Invention patent for IMM40H was authorized by the US Patent and Trademark Office

On November 17, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the newly developed humanized IgG1 anti- CD70 monoclonal antibody (project number: IMM40H) has been authorized by the US Pa......

2022-11-17

ImmuneOnco Published crystal protein structure of IMM01

On August 31, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced the publication of the crystal protein structure of IMM01. The tittle of the paper is " Crystal Structure of Human CD47 i......

2022-08-31

IMM40H was approved almost simultaneously by China NMPA and US FDA for clinical trial research

On August 29, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that the newly developed humanized IgG1 CD70 antibody (project number: IMM40H) has been approved by the US FDA and......

2022-08-29

ImmuneOnco won "Drug Innovation Award" by Securities Times

On August 6, 2022, the Securities Times Biomedical Innovation Forum and the 2nd Drug Innovation Award Ceremony hosted by the Securities Times were held in Shanghai. Chairman founder of ImmuneOnco，Dr.Tian, Wenzhi,, was successfully selected a...

2022-08-06

IMM2902 is granted Fast Track designation for breast cancer by the U.S. FDA

On July 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that the first global CD47×HER2 bispecific molecule (IMM2902) have received Fast Track Designation (FTD) from the U.S. Food......

2022-07-15